Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel ...

Quest expects the new blood test will support response monitoring in clinical trials.

SARASOTA, FL, UNITED STATES, January 28, 2026 / EINPresswire.com / — Identifyn ®, a leader in super-resolution applications ...

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...

Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...

Waters has announced the completion of its acquisition of BD’s Biosciences and Diagnostic Solutions businesses.

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...

The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...

Neuberg Sehgal Path Lab, a leading name in diagnostic services, launched a cutting-edge cytogenetics testing technology at ...

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.